Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6DDO

Crystal structure of the single mutant (D52N) of the full-length NT5C2 in the basal state

6DDO の概要
エントリーDOI10.2210/pdb6ddo/pdb
分子名称Cytosolic purine 5'-nucleotidase, PHOSPHATE ION (3 entities in total)
機能のキーワードhydrolase
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計134291.35
構造登録者
主引用文献Dieck, C.L.,Tzoneva, G.,Forouhar, F.,Carpenter, Z.,Ambesi-Impiombato, A.,Sanchez-Martin, M.,Kirschner-Schwabe, R.,Lew, S.,Seetharaman, J.,Tong, L.,Ferrando, A.A.
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Cancer Cell, 34:136-147.e6, 2018
Cited by
PubMed Abstract: Activating mutations in the cytosolic 5'-nucleotidase II gene NT5C2 drive resistance to 6-mercaptopurine in acute lymphoblastic leukemia. Here we demonstrate that constitutively active NT5C2 mutations K359Q and L375F reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric activator. In contrast, most relapse-associated mutations, which involve the arm segment and residues along the surface of the inter-monomeric cavity, disrupt a built-in switch-off mechanism responsible for turning off NT5C2. In addition, we show that the C-terminal acidic tail lost in the Q523X mutation functions to restrain NT5C2 activation. These results uncover dynamic mechanisms of enzyme regulation targeted by chemotherapy resistance-driving NT5C2 mutations, with important implications for the development of NT5C2 inhibitor therapies.
PubMed: 29990496
DOI: 10.1016/j.ccell.2018.06.003
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.48 Å)
構造検証レポート
Validation report summary of 6ddo
検証レポート(詳細版)ダウンロードをダウンロード

227561

件を2024-11-20に公開中

PDB statisticsPDBj update infoContact PDBjnumon